Sense of urgency, Brian Druker
Interviewee: Brian Druker. Brian Druker talks about sense of urgency.
I think one of the advantages I've had is that as a cancer doctor I can go to the clinic and see patients who right now today need something better. And by carrying that back to the lab I've always had this sense of urgency. I need to be working harder; I need to be moving things along. And nowhere was that more apparent than in the years 1996 to 1998. we had completed a fair bit of our preclinical work, our laboratory work with Gleevac, but we needed to get that drug into clinic and there are a handful of patients, CML patients that I have from those years that aren't with me any more. When I lose one I would redouble my effort to make sure that I was moving that drug into clinic because if it had a chance of saving the next person I wanted to make sure that we got it to those patients before it was too late. And I think having that sense of urgency is really what's helped me get to where I am.
chronic myeloid leukemia,cml patients,brian druker,gleevac,sense of urgency,cancer doctor,cancer drug,gleevec,laboratory work,leukemia,handful
Brian Druker talks about how Gleevec has restored patients' hope for the future.
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.
Professor Charles Sawyer explains that Gleevec is a pill taken once a day and works remarkably well in all phases of CML.
Professor Charles Sawyer explains that CML stands for chronic myeloid leukemia, which is a blood cancer and it is different from many cancers because it starts very slowly and patients when they're first diagnosed don't have many symptoms.
Professor Charles Sawyer explains that EGF receptor happens to be the driver in at least 10% of lung cancer patients in the U.S.
Professor Charles Sawyer explains that the CML clone makes mistakes in DNA replication and generates a diverse repertoire of mutations.
Brian Druker talks about how the drug he designed targets the molecular cause of CML.
Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.